ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Protagonist Therapeutics Initiates PTG-200 Phase 1 Trial
americanpharmaceuticacreview
November 10, 2017Protagonist Therapeutics announced the initiation of dosing in a Phase I healthy volunteer study of PTG-200, a potential first-in-class, gastrointestinal-restricted, oral peptide interleukin (IL)-23 receptor antagonist.
Pharma Sources Insight July 2025
